Patents Assigned to The Government of The United States as Represented by The Secretary of Health
-
Patent number: 11065332Abstract: Regional, tumor-targeted, cytotoxic therapy, such as D2C7-immunotoxin (D2C7-IT), not only specifically target and destroy tumor cells, but in the process initiate immune events that promote an in situ vaccine effect. The antitumor effects are amplified by immune checkpoint blockade which engenders a long-term systemic immune response that effectively eliminates all tumor cells.Type: GrantFiled: November 4, 2016Date of Patent: July 20, 2021Assignees: Duke University, The Government of The United States as Represented by the Secretary of Health and Human Services, National Institutes of HealthInventors: Darell Bigner, Vidyalakshmi Chandramohan, Smita Nair, Matthias Gromeier, Xuhui Bao, Ira H. Pastan
-
Publication number: 20180311346Abstract: Regional, tumor-targeted, cytotoxic therapy, such as D2C7-immunotoxin (D2C7-IT), not only specifically target and destroy tumor cells, but in the process initiate immune events that promote an in situ vaccine effect. The antitumor effects are amplified by immune checkpoint blockade which engenders a long-term systemic immune response that effectively eliminates all tumor cells.Type: ApplicationFiled: November 4, 2016Publication date: November 1, 2018Applicants: Duke University, THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN, SERVICES, NATIONAL INSTITUTES OF HEALTHInventors: Darell Bigner, Vidyalakshmi Chandramohan, Smita Nair, Matthias Gromeier, Xuhui Bao, Ira H. Pastan
-
Publication number: 20170051064Abstract: We tested the in vitro and in vivo efficacy of a recombinant bispecific immunotoxin that recognizes both EGFRwt and tumor-specific EGFRvIII receptors. A single chain antibody was cloned from a hybridoma and fused to toxin, carrying a C-terminal peptide which increases retention within cells. The binding affinity and specificity of the recombinant bispecific immunotoxin for the EGFRwt and the EGFRvIII proteins was measured. In vitro cytotoxicity was measured. In vivo activity of the recombinant bispecific immunotoxin was evaluated in subcutaneous models and compared to that of an established monospecific immunotoxin. In our preclinical studies, the bispecific recombinant immunotoxin, exhibited significant potential for treating brain tumors.Type: ApplicationFiled: October 11, 2016Publication date: February 23, 2017Applicants: Duke University, THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES , NInventors: Darell D. Bigner, Chien-Tsun Kuan, Ira H. Pastan, Charles Pegram
-
Publication number: 20160272730Abstract: High affinity antibodies were made to gangliosides expressed on tumor cells. The antibodies can be used analytically, diagnostically, therapeutically, and theranostically. The antibodies may be used to target cytotoxic reagents to tumor cells, thus minimizing full-body toxicity. The antibodies may also be used with out added cytotoxin. The antibodies may be detectably labeled or labelable for analytic and diagnostic purposes. The combination of specificity and affinity of the antibodies render them particularly useful.Type: ApplicationFiled: June 2, 2016Publication date: September 22, 2016Applicants: Duke University, THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF HEALTHInventors: Darell Bigner, Chien-Tsun Kuan, Ira H. Pastan, Hailan Piao
-
Publication number: 20130171178Abstract: XAGE-1 is a gene expressed in a number of important human cancers, including prostate cancer, lung cancer, breast cancer, ovarian cancer, glioblastoma, pancreatic cancer, and melanoma. It has now been discovered that peptides of fifty or fewer amino acids comprising the sequence X1X2X3PSAPSPX4 (SEQ ID NO:5), where X1 is any amino acid and is preferably G or Y; X2 is selected from the group consisting of L, M, A, I, V, and T, with L and M being preferred; X3 is a hydrophobic residue, M or A; and X4 is V, M, L, A, I, or T, and is preferably V, bind to the HLA-A2 MHC class I molecule, and can be used to raise immune responses to XAGE-1-expressing cancers. In some embodiments, the P at position 7, the S at position 8, or the P at position 9, can be omitted to create a 9 amino acid peptide.Type: ApplicationFiled: December 13, 2004Publication date: July 4, 2013Applicant: THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICESInventors: Jay A. Berzofsky, Ira H. Pastan, Masaki Terabe
-
Publication number: 20120122121Abstract: The invention provides high affinity antibodies suitable for forming Immunotoxins that inhibit the growth of cells expressing human glycoprotein NMB, including glioblastoma multiform cells, anaplastic astrocytoma cells, anaplastic oligodendroglioma cells, oligodendroglioma cells, and melanoma cells.Type: ApplicationFiled: October 18, 2011Publication date: May 17, 2012Applicants: Duke University, The Government of The United States as Represented by The Secretary of HealthInventors: Chien-Tsun KUAN, Darell D. BIGNER, Ira H. PASTAN